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ABSTRACT Fungalcellwallsarepredominantlycomposedofglucans,mannans,andchitin.Recognitionoftheseglycansbythe
innateimmunesystemisacriticalcomponentofhostdefensesagainstthemycoses.Complement,animportantarmofinnate
immunity,playsasigniﬁcantroleinfungalpathogenesis,especiallythealternativepathway(AP).Herewedeterminethatthe
glycanmonosaccharidecompositionandglycosidiclinkagesaffectAPactivationandC3deposition.Furthermore,properdin,a
positiveregulatoroftheAP,contributestothesefunctions.APactivationbyglycanparticlesthatvariedincompositionand
linkagewasmeasuredbyC3agenerationinserumtreatedwith10mMEGTAand10mMMg2(Mg-EGTA-treatedserum)(AP
speciﬁc;properdinfunctional)orMg-EGTA-treatedserumthatlackedfunctionalproperdin.Particlesthatcontainedeither
1¡3or1¡6glucansorbothgeneratedlargeandsimilaramountsofC3awhentheAPwasintact.Blockingproperdinfunc-
tionresultedin5-to10-fold-lessC3aproductionbyparticulate 1¡3glucans.However,particulate 1¡6glucansgenerated
C3aviatheAPonlyinthepresenceofintactproperdin.Interestingly,zymosanandglucan-mannanparticles(GMP),whichcon-
tainboth-glucansandmannans,alsorequiredproperdintogenerateC3a.The 1¡4glycanschitinandchitosanminimally
activatedC3evenwhenproperdinwasfunctional.Finally,properdinbindingtoglucanparticles(GP)andzymosaninserum
requiredactiveC3.ProperdincolocalizedwithboundC3,suggestingthatinthepresenceofserum,properdinboundindirectly
toglycansthroughC3convertases.TheseﬁndingsprovideabetterunderstandingofhowproperdinfacilitatesAPactivationby
fungithroughinteractionwiththecellwallcomponents.
IMPORTANCE Invasivefungalinfectionshaveincreasedinincidencewiththewidespreaduseofimmunosuppressivetherapyand
invasiveprocedures.Activationofthecomplementsystemcontributestoinnateimmunityagainstfungibygeneratingchemoat-
tractantsthatrecruitwhitebloodcellsandbycoatingthepathogenwithcomplementfragmentsthat“mark”themforphagocy-
tosis.Thefungalcellwallactivatescomplementinanantibody-independentmannerthroughthealternativepathway(AP).Pro-
perdinisapositiveregulatoroftheAP.ThisstudyelucidateshowthespeciﬁcityofcellwallglycanlinkagesaffectsAPactivation
andtheroleproperdinplaysinthisprocess.Particulate 1¡3glucansactivatedtheAPevenintheabsenceofproperdin,while
1¡6glucansrequiredproperdinforAPactivation.Incontrast,the 1¡4glycanschitinandchitosanfailedtoactivatetheAP.
Theseﬁndingsenhanceourmechanisticunderstandingofhowfungiactivatecomplementandhaveimplicationsfortheuseof
glycansinbiomedicalapplications.
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C
omplement activation, a critical component of host defenses
against fungal infection (1–3), can proceed by three well-
deﬁned pathways. Classical pathway activation is mainly initiated
when antibody is complexed to antigens. The lectin pathway
shares structural similarities to the classical pathway but is trig-
gered by binding to mannose and ﬁcolins. The third complement
activationpathway,thealternativepathway(AP),doesnotrequire
antibody or lectins for its initiation. Rather, initiation of the AP
occurs by spontaneous low-rate hydrolysis of the thioester in C3,
which results in continuous supply of C3(H2O) in solution (4).
Thehalf-lifeoftheactivatedC3thioesterhasbeenestimatedtobe
~60s(5).BindingoffactorBtoC3(H2O)andcleavageofbound
factor B to Bb by the enzyme factor D lead to the formation of the
initial AP C3 convertase [C3(H2O)Bb]. This ﬂuid-phase C3 con-
vertase can cleave C3 to release C3a and C3b, and the latter can
covalently bind to microbial surfaces. Binding of factor B to
surface-boundC3binthepresenceoffactorDleadstotheforma-
tion of an AP C3 convertase (C3b,Bb) that cleaves additional C3
molecules. This positive C3 ampliﬁcation loop is a key feature of
the AP. The AP C3 convertase C3b,Bb has a half-life of only
1.5 min. Properdin carries out the important function of binding
toandstabilizingtheC3b,Bbcomplex,therebyincreasingitshalf-
life 5- to 10-fold (6). Properdin is the only known positive regu-
lator of the complement system.
Properdin is found in serum at a concentration of 4 to
25 g/ml (7–11). Properdin is stored in neutrophils as secondary
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toplayakeyroleindetermininglocalAPactivity(10).Individuals
with properdin deﬁciency are predisposed to severe invasive me-
ningococcalinfections,oftenwithahighermortalitythanhealthy
individuals (13–15).
Althoughinterspeciesandintraspeciesvariationsarecommon,
most fungal cell walls feature an inner layer composed of
-glucans and chitin, and the inner layer is wholly or partially
masked by covalently linked cell surface mannoproteins (16–18).
MannansconsistofpolymersofmannoseaddedtoproteinsviaN-
orO-linkages.The-glucanlayerpredominantlycomprises-1,3
linkages, with a minority (9 to 20%) of glucans linked by a -1,6
bond(18,19).Glucanparticles(GP),highlypuriﬁedSaccharomy-
ces cerevisiae cell walls composed of -1,6 branched -1,3 glucans
have been suggested as an antigen delivery vehicle because their
polysaccharide composition provides receptor-targeted delivery
to phagocytic antigen-presenting cells and their hollow and po-
rous structure allows for high antigen loading (20, 21). -Glucan
preparations derived from fungi such as Saccharomyces cerevisiae
have a record of safety in both preclinical and human trials (22–
24). These ﬁndings support the clinical development of glucan
particles as a vaccine delivery platform and immunoadjuvant.
Deciphering the mechanistic basis for how fungal cell walls
activate complement is important not only for understanding
host defenses and fungal pathogenicity but also for the safe and
effective design of fungal glycan-based biotherapies. More than
25yearsago,CzopandAusten(25)demonstratedthataggregated
-glucansderivedfromyeastwerepotentactivatorsofthehuman
AP. In this study, we have extended those observations and have
deﬁned the role of properdin in activating the AP in a linkage-
speciﬁcmanner.Thesestudiesprovideimportantmechanisticin-
sights into the role of properdin in complement activation on
fungal glucans, which could affect downstream events in the im-
muneresponse,suchasleukocyterecruitment,neutrophilactiva-
tion, and T cell skewing.
RESULTS
C3 is deposited on GP through the AP.
Complement-dependent C3 fragment de-
position on glucan particles (GP) (contains
both 1¡3 and 1¡6 D-glycosidic link-
ages)wasmeasuredbyﬂowcytometry.The
alternative pathway (AP) (normal human
serum [NHS] treated with 10 mM EGTA
and 10 mM Mg2 [Mg-EGTA-NHS]) ac-
counted for C3 deposition at 30 min; addi-
tion of the lectin and classical pathways
(NHS) did not increase C3 deposition
(Fig.1,leftpanel).Theseresultsweresimilar
to those observed with zymosan, which is
known to activate C3 through the AP (26)
and used here as a positive control. Al-
though zymosan displayed the same results
qualitatively, less C3 deposition was ob-
served (Fig. 1, right panel). To ensure that
chelatingCa2withEGTAdidnotaffectthe
assays,wealsousedC2-depletedserum(AP
alone,functional)andconﬁrmedtheresults
(data not shown); Mg-EGTA-treated se-
rumwasemployedfortheremainderofthe
study.
Properdin facilitates AP-mediated C3 deposition on GP.
ProperdinistheonlyknownpositiveregulatoryproteinoftheAP
(6), and we speculated that it facilitated deposition of C3 frag-
ments on GP. We used confocal microscopy to assess whether C3
and properdin localized as predicted by the traditional model of
properdinbindingtoalternativepathwayC3/C5convertases(26–
28). As a prelude to confocal microscopy experiments, we exam-
ined several concentrations of Mg-EGTA-NHS with functioning
properdin or Mg-EGTA-NHS where properdin function was
blockedwithmonoclonalantibody(MAb)A233(Quidel),andwe
found that a serum concentration of 40% (vol/vol) (40% NHS),
which had been optimized for measuring C3 deposition by
ﬂuorescence-activated cell sorting (FACS), was also suitable for
confocal experiments. GP or zymosan was incubated with either
40% NHS treated with 10 mM EGTA and 10 mM Mg2 (40%
NHS–Mg-EGTA)or40%humanproperdin-depletedserum,and
the reactions were stopped at 10, 15, 20, and 30 min by adding
EDTA. C3 deposition was detected using ﬂuorescein isothiocya-
nate (FITC)-conjugated anti-human C3c, and bound properdin
was detected using anti-human properdin followed by anti-
mouseIgGconjugatedtoAlexaFluor647.At10min,discretefoci
with colocalization of C3 and properdin were observed on both
GP and zymosan particles (Fig. 2A). With time, C3 deposition
spread over the entire surfaces of the particles, while properdin
binding continued at discrete locations of C3b binding (Fig. 2A
andB,mergedcolumns).Intheabsenceofproperdin,theamount
of C3 fragments deposited on both GP and zymosan particles was
greatlyreduced(Fig.2BshowsminimalC3depositionat30min),
highlighting the importance of properdin in facilitating C3 depo-
sition on these particles.
ProperdinbindstoGPonlyinthepresenceofC3inthecon-
text of human serum. Previous studies have shown that native
forms of puriﬁed properdin can bind directly to certain AP acti-
vator surfaces, including zymosan in non-serum-containing sys-
FIG 1 The alternative pathway (AP) mediates C3 deposition on glucan particles (GP) and zymosan.
Total C3 deposited on GP and zymosan was measured by ﬂow cytometry. GP and zymosan were
incubated with either normal human serum (NHS) (all complement pathways active; dotted black
lines),NHStreatedwith10mMEGTAand10mMMg2(NHS-Mg/EGTA)(onlyAPactive;solidblack
line), or heat-inactivated NHS (no active complement; solid grey histograms). The ﬁnal concentration
ofseruminallreactionmixtureswas40%.TotalC3(C3bandiC3b)depositedontheglycansurfacewas
measured by ﬂow cytometry using sheep polyclonal anti-human C3c conjugated to FITC. The dashed
blacklinerepresentsacontrolwhereparticleswereincubatedwithFITCconjugatedC3cantibodyalone
(human serum was omitted from the reaction mixture). The x axis represents ﬂuorescence on a log10
scale, and the y axis shows the number of events (counts). The numbers adjacent to the histograms
representthemedianﬂuorescenceintensityofC3binding.Theresultsofonerepresentativeexperiment
of two reproducibly repeated experiments are shown.
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ponent(s) may interfere with binding of properdin directly to
alternative pathway activator surfaces (30), we questioned
whether properdin could bind directly to GP and zymosan parti-
clesinthecontextofserum.C3-depletedserumwasusedtoelim-
inateC3depositiononGPandzymosantoexaminewhetherpro-
perdin would bind directly to GP and zymosan surfaces [or
possibly through a serum component(s) distinct from C3]. There
was no detectable properdin binding to GP or zymosan by FACS
analysis in C3-depleted serum over baseline ﬂuorescence levels
seen with properdin-depleted serum (Fig. 3A). Reconstitution of
C3-depleted serum with physiological concentrations of puriﬁed
FIG 2 The kinetics and location of C3 deposition and properdin binding on GP and zymosan particles by confocal microscopy. (A) GP and zymosan particles
were incubated with 40% NHS– Mg-EGTA (40% NHS treated with 10 mM EGTA and 10 mM Mg2), and the reaction was stopped by adding 10 mM EDTA at
the indicated time points. C3 deposited on particles was detected with sheep polyclonal anti-human C3c conjugated to FITC (green) (C3 - FITC columns), and
properdin (P) binding was detected with an antiproperdin MAb (A235; Quidel MAb 235) followed by Alexa Fluor 647-labeled anti-mouse IgG (red) (P – A657
columns).ThemergedcolumnsarethemergedimagesofC3andproperdinbinding.(B)ProperdinisrequiredformaximalC3depositiononGPandzymosan.
GPandzymosanwereincubatedwith40%serum(Mg-EGTA-treatedserumdepletedofproperdin).C3andPbindingweredetectedasdescribedaboveforpanel
A.Thephase-contrastimagesareshownintheleftmostcolumn,andthephase-contrastandC3imagesweremergedandareshownintherightmostcolumn.The
images were taken using a 63 lens and imaged with a Leica TCS SP2 AOBS laser scanning confocal microscope (Leica, Wetzlar, Germany).
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tometry (Fig. 3A). These results were conﬁrmed using confocal
microscopy(Fig.3B),whereproperdinboundtoGPandzymosan
occurredonlywhenactiveC3waspresentintheserum,notwhen
C3-depleted serum was used. These data provide evidence that
properdininhumanserumdoesnotbinddirectlytoGPorzymo-
san but associates with alternative pathway C3/C5 convertases
that bound to GP and zymosan.
GlycanlinkagespeciﬁcityandinﬂuenceofproperdinonAP-
mediated release of C3a and C5a. GP are primarily composed of
1¡3 and 1¡6 glucan linkages (21, 31), while zymosan com-
prises 1¡3 and 1¡6 -glucans and mannans (32, 33). In ad-
dition to 1¡3 and 1¡6 linkages, fungal glucans contain a
small fraction of chitin composed of 1¡4 glycosidic linkages
(34–36). Both GP and zymosan also contain a small fraction of
chitin. We examined whether glycan linkage speciﬁcity affected
activation of the AP using glycan particles from an array of
sources, which are listed in Table 1. In addition, three soluble
glycans (dextran, laminarin, and mannan), representing several
glycan linkages, were used as negative controls because soluble
glycans are poor AP activators (25).
Activation of AP generates the C3 convertase C3b,Bb that
cleaves the  chain of C3 and releases the N-terminal 9-kDa C3a
fragment. Cleavage of the C3a fragment is accompanied by expo-
sure of a labile internal thioester bond in the resulting = chain of
C3b. The C3b molecule must bind to a surface target (in this
instance, the glycan particle) through a covalent ester or amide
bond. Failure to do so results in hydrolysis of the internal thio-
ester, leaving the C3b unbound in solution. Continued comple-
ment activation results in formation of the AP C5 convertase
(C3bC3b,Bb) that cleaves C5 and releases the C5a fragment. We
used enzyme-linked immunosorbent assay (ELISA) to measure
the amounts of C3a and C5a generated by particulate and soluble
glycansthatactivatedtheAP.Glucanparticlesthatcontainedonly
1¡3 linkages (curdlan) or 1¡6 linkages (pustulan) or both
1¡3 and 1¡6 linkages (GP and scleroglucan) were potent
activators of AP, generating high levels of C3a and C5a (Fig. 4A
and C). In contrast, particles that comprised only 1¡4 linkages
of amino N-acetylglucosamine and N-glucosamine (chitin and
chitosan) failed to signiﬁcantly activate AP above baseline levels.
As expected, zymosan, a known AP activator that contains both
-glucans and mannans, generated high levels of C3a and C5a.
FIG 3 Properdin in serum binds to GP and zymosan particles only in the presence of active C3. Properdin binding to GP and zymosan was detected following
incubation of the particles with C3-depleted serum and C3-depleted serum reconstituted with puriﬁed C3. The ﬁnal concentration of serum in all reaction
mixtureswas40%.Normalhumanserum(NHS)andproperdin-depleted(P-depleted)serumwereusedaspositiveandnegativecontrolsforproperdinbinding,
respectively.(A)Glycan-boundproperdinwasdetectedbyﬂowcytometryusinganantiproperdinMAb(A235;Quidel)followedbyanti-mouseIgGconjugated
to Alexa Fluor 647. In all graphs, the x axis shows ﬂuorescence on a log10 scale, and the y axis shows the number of events. Numbers adjacent to the histogram
representthemedianﬂuorescenceintensityofproperdinbinding.(B)PoperdinbindingtoGPandzymosanbyconfocalmicroscopy.Usingconditionsdescribed
aboveforpanelA,theparticleswerestainedforproperdinusinganantiproperdinMAbandAlexaFluor647.Thephase-contrastimages,properdinstaining(red)
(middlecolumn),andmergedimagesofthephase-contrastandproperdinimagesareshownintheright-handcolumn.Theimageswerecollectedandanalyzed
as described in the legend to Fig. 2. The results of one representative experiment of two separate and reproducibly repeated experiments are shown.
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properdin [Fig. 1 and 3]) and zymosan (low C3, high properdin
[Fig. 1 and 3]) was reﬂected in the generation of C3a and C5a by
theAPwithfunctionalproperdin.Zymosangenerated78%ofC3a
and 93% of C5a production achieved by GP only in serum with
intact AP that contained active properdin (Fig. 4A and C). In
accordance with previous work (25), none of the soluble glycans
activated AP signiﬁcantly above activation of AP by serum alone.
Next we determined whether AP activation mediated by gly-
cans with different linkages required properdin. Interestingly,
TABLE 1 Glycans used in this study
Glycan Species [source or reference(s)] Composition and linkage
Particulate glycans
Curdlan Alcaligenes faecalis (Sigma) 1¡3 D-glucose
GP Saccharomyces cerevisiae (21, 31) 1¡3 and 1¡6 D-glucose and trace 1¡4 D-N-acetylglucosamine
Scleroglucan Sclerotium glucanicum (Cargill) 1¡3 and 1¡6 D-glucose
Pustulan Umbilicaria pustulata (Calbiochem) 1¡6 D-glucose
Chitin Chionoecetes opilio (Seikagaku) 1¡4 D-N-acetylglucosamine
Chitosan Chionoecetes opilio (Primex) 1¡4 D-N-glucosamine
Zymosan Saccharomyces cerevisiae (Sigma) -Glucans, mannans, and trace 1¡4 D-N-acetylglucosamine
GMP Saccharomyces cerevisiae (31) -Glucans, mannans, and trace 1¡4 D-N-acetylglucosamine
Soluble glycans
Dextran Leuconostoc mesenteroides (Sigma) 1¡6 D-glucose
Laminarin Laminaria digitata (Sigma) 1¡3 and 1¡6 D-glucose
Mannan Saccharomyces cerevisiae (Sigma) 1¡6 D-mannose
FIG 4 Role of properdin in alternative pathway activation by glycan particles. C3a or C5a resulting from 30 min of incubation of each of the particulate and
soluble glycans listed in Table 1 in 40% NHS–Mg-EGTA with or without properdin. C3a or C5a concentrations (ng/ml; shown on the y axis) were measured in
supernatants using MicroVue C3a or C5a enzyme immunoassay kits. (A) C3a generation by glycans incubated in NHS-Mg-EGTA (properdin intact). (B) C3a
generation by glycans incubated in NHS-Mg-EGTA in the presence of an antiproperdin monoclonal antibody A233 that blocked functional properdin (anti-P
mAb). (C and D) C5a generated by glycans incubated in 40% NHS–Mg-EGTA (C) and C5a generated by glycans incubated in 40% NHS–Mg-EGTA plus
antiproperdinMAb(D).ThebrokenhorizontallineindicatesbaselineC3aorC5agenerationby40%NHS–Mg/EGTAalone(AandC)or40%NHS–Mg/EGTA
plusantiproperdinMAbalone(BandD)(alsoindicatedbybarslabeled“Control”).TheparticlelinkagesareindicatedabovethebarsinpanelsAandC.Results
areexpressedasmeansstandarddeviations(SD)(errorbars)oftwoorthreeseparateexperiments;eachreactionwasperformedinduplicate.Notethedifferent
scalesoftheyaxes.StatisticalanalysiswasperformedusingANOVA.ThestatisticalsigniﬁcanceoftheamountsofC3aandC5ageneratedwascalculatedbetween
the amounts of C3a and C5a generated by NHS-Mg-EGTA in the presence or absence of functional properdin alone compared to the amounts of glycans
incubated with corresponding serum. The statistical signiﬁcance is represented in red above the bars as follows: ***, P  0.001; **, P  0.01; and ns (for not
signiﬁcant), P  0.05.
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scleroglucan) generated C3a and C5a above baseline levels when
properdin function was blocked. Pustulan (1¡6 linkages only)
didnotactivateAPintheabsenceofproperdinfunction(Fig.4B).
Although the total amounts of C3a and C5a generated in the ab-
sence of functional properdin were, on average, 10-fold less than
when properdin was active, it is worth noting that the amounts of
C3a and C5a spontaneously generated in the control reactions
(serum plus buffer alone) when properdin was nonfunctional
were ~30-fold and ~5-fold less for C3a and C5a generation, re-
spectively (Fig. 4A and B and Fig. 4C and D, respectively). As
expected, chitin, chitosan, and the soluble glycans did not gener-
ate C3a and C5a when properdin was nonfunctional. Interest-
ingly,zymosanandGMP(bothconsistingof-glucans,including
1¡3 and 1¡6 glucans and mannans) generated C3a and C5a
in the presence of Mg-EGTA-treated NHS (properdin active) but
didnotsigniﬁcantlydosointheabsenceofproperdin.SimilarC3a
and C5a generation were observed using Mg-EGTA-treated
properdin-depleted serum (data not shown).
Inﬂuence of properdin on the deposition of C3 fragments
onto glycan particles. Deposition of C3b on the surface of a gly-
can particle reﬂects the number of proximate –OH groups that
can serve as electron donors to form covalent ester bonds with
activated C3b. We characterized C3 deposition on different par-
ticles by Western blotting. The 75-kDa  chain present in both
C3b and iC3b, freed by reducing conditions prior to SDS-PAGE
and Western blotting, is a measure of total C3 deposited onto
particles (Fig. 5A). The amount of C3 deposited onto a particle
may be paralleled by the amount of C3a and C5a generated, al-
thoughproperdinbindingalsoenhancesC3aandC5aproduction
by prolonging the survival of the AP C3 and C5 convertases that
result in increased cleavage of C3 and C5. This is exempliﬁed
aboveforzymosanparticles(Fig.4AandC).Inaddition,linkage
speciﬁcity of the glucans also accounted for differences in C3 de-
position.
Figure 5 shows that among the 1¡3 and/or 1¡6 linkage-
containing glucans, C3b was deposited when the AP was fully
active in the presence of functional properdin (Fig. 5B), but little
FIG 5 C3 fragment deposition on the -glycan particles. (A) Schematic representation of C3 degradation products. (B) Particles were incubated with 40%
NHS–Mg/EGTA, washed, and digested with 4 LDS sample buffer containing 10% -mercaptoethanol. Samples were electrophoresed ona4t o1 2 %Bis-Tris
gel,andWesternblottingwasperformed.C3fragmentswereidentiﬁedusingafﬁnity-puriﬁedsheepanti-humanC3antibody.Controlsincluded2lofthe200
diluted NHS-Mg-EGTA (labeled Control), puriﬁed C3, C3b, and iC3b (6.25 ng of each protein per lane). (C) C3 fragments bound to the glycan particles in the
absence of functional properdin. The particles were incubated in 40% NHS–Mg/EGTA that contained antiproperdin MAb 233 (anti-P mAb) and processed as
described above for panel B, and Western blotting was performed as described above. Controls are described above for panel B, except that all specimens
contained antiproperdin MAb 233. The identities of the C3 fragments are indicated in parentheses on the right ( C3). The results of one representative
experiment of three separately performed and reproducibly repeated experiments are shown. kD, kilodaltons.
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(1¡6glucan)andonzymosanandGMP(Fig.5BandC).Inthe
absence of functional properdin, only the 1¡3 linkage-
containing glucans (curdlan, GP, and scleroglucan) bound C3,
consistent with their ability to generate C3a and C5a under these
conditions (Fig. 4B and D); minimal C3 was deposited on pustu-
lan, zymosan, and GMP in the absence of functional properdin.
Collectively, our data suggest that when properdin is func-
tional, 1¡3 and 1¡6 linkage-containing glucans are potent
activators of the alternative pathway. However, in the absence of
functional properdin, only 1¡3 linkage-containing glucans can
activate the alternative pathway, albeit to a much lower level than
when properdin is functional. In the case of zymosan and GMP,
1¡3 glycans that are present may be less exposed at the surface
because the outer mannan “layer” shields the glycans from inter-
acting with C3 molecules.
DISCUSSION
We have deﬁned how monosaccharide composition and linkage
speciﬁcity of -glucans (1¡3 and 1¡6 linked) together inﬂu-
ence activation of the alternative pathway (AP). Importantly, the
role played by properdin in linkage-speciﬁc -glucan-mediated
AP activation has also been deﬁned. -Glucans are found natu-
rally in fungi, algae, plants, and some bacteria; both 1¡3 and
1¡6 glucans are major constituents of the cell walls of fungi. A
small percentage of the fungal cell wall is composed of chitin
(1¡4 D-N-acetylglucosamine). As shown previously (25), we
alsodemonstratedthatallglycanparticles(GP)witheither1¡3
and/or1¡6glucanlinkageactivatedC3whentheAPwasintact.
In contrast, chitin or chitosan (1¡4 linkages) activated the AP
(measured by C3a and C5a generation) only minimally. In the
absenceoffunctionalproperdin,onlyglucanparticlesthatexpress
surface-exposed 1¡3 linkages (GP, scleroglucan, and curdlan)
generated C3a and C5a, albeit at concentrations about 10-fold
lower than when properdin was functional. Pustulan (contains
only1¡6glucanlinkages)wasapotentAPactivatorinthepres-
enceofproperdinbutgeneratedminimalC3aandC5awhenpro-
perdin function was blocked. These data suggest that glucan par-
ticles that express surface-exposed 1¡3 glucan linkages can
activate C3 in the absence of properdin, but particles with only
1¡6 glucan linkages require properdin to activate C3.
Following C3 activation, the metastable C3b molecule must
quickly bind to an electron-donating –OH group through the
thioester bond; failure to do so results in hydrolysis of the thioes-
ter,andtheC3bmoleculeremainsinsolution.FreeC3bcanform
alternative pathway C3 and C5 convertases (C3b,Bb and
C3bC3b,Bb) in solution that can further activate C3 and C5 and
generatemoreC3aandC5a,respectively.However,theamountof
C3b deposited on the glycan particles depends on the availability
of hydroxyl (–OH) groups on ringed monosaccharides, princi-
pally hexoses, and serves to explain the apparent discordance be-
tween C3a and C5a generation (Fig. 4A and C) and C3 fragment
deposition (Fig. 5B). The particulate 1¡3 glucans used in this
studyexistprimarilyinatriplehelixconformation(37).Basedon
the results of glucan ﬁber diffraction studies (37), the hydroxyl
groups at positions 2 and 4 are buried within the polysaccharide
chain participating in intra- and interchain hydrogen bonds. The
hydroxyls at position 6 are exposed to solvent and are the likely
electron donors for reaction with C3. Removal of primary –OH
groups from position 6 of monosaccharides decreases the efﬁ-
ciency of C3 binding (38). Consistent with our observations
(Fig. 5B), the 1¡3 particulate glucans with exposed free –OH
groups at position 6 (curdlan, GP, and scleroglucan) bound C3
moreeffectivelythan1¡6glucans,whoseposition6isoccupied
by the linkage to the adjacent monosaccharide (pustulan). Also
consistent with our observations, the 1¡3 particulate glucans
withfree–OHgroupsatposition6maskedbymannans(zymosan
and glucan-mannan particles [GMP]) bound C3 less effectively.
Higher efﬁciency of 1¡3 glucan binding to nascent C3 likely
facilitates C3b binding to –OH at position 6, even when the AP
lacks properdin (Fig. 5C).
Release of anaphylatoxins C3a and C5a during activation of
complementhasalsobeenshowntopromoteneutrophilinﬂuxto
sites of infection. Human neutrophils release properdin upon
stimulation (12), which likely serves to augment AP activation
(39). 1¡6 glucans, in particular, stimulate human neutrophils
and mediate engulfment, production of reactive oxygen species,
andexpressionofheatshockproteinsmoreefﬁcientlythan1¡3
glucans (40). In one study, human neutrophils rapidly ingested
beadscoatedwith1¡6glucan,butnotbeadscoatedwith1¡3
glucan (40), suggesting that stimulation of neutrophils may be
directedbythespeciﬁclocationofC3bbindingonglycansurfaces.
The effects may not be limited to neutrophils, as recently, it was
shown that C3a and C5a generation can regulate interleukin 17A
(IL-17A) responses (41), a critical component of host defense
against many fungal infections. Selective reduction of properdin
functionmaybeoftherapeuticbeneﬁt.Forexample,inamodelof
cardiopulmonary bypass, treatment with antiproperdin anti-
bodies resulted in signiﬁcantly reduced neutrophil and platelet
activation (14). However, our data suggest that neutralizing pro-
perdin could increase the risk of fungal infections by decreasing
AP activation.
In addition to affecting innate immune responses, generation
of C3a and C5a can affect adaptive immune responses (41, 42).
For example, recently, Lajoie et al. demonstrated the abilities of
C3a and C5a to reciprocally regulate TH1 and TH17 responses in
an airway hyperresponsiveness mouse model (41). As TH1 and
TH17 responses are critical components of host defense against
many fungal infections (43, 44), the contribution of complement
activation by fungal cell walls to TH skewing deserves further
study.
We have shown that puriﬁed properdin in its native forms
(dimers,trimers,ortetramers)bindsdirectlytozymosan(27,29),
but data from the present study suggest that properdin does not
bind directly to either GP or zymosan in the context of serum but
instead binds to deposited C3 (Fig. 3A and B). Thus, it seems
unlikely that properdin itself initiates AP activation in the pres-
enceofserum,conﬁrmingthatproperdinservestostabilizeAPC3
convertases (26–28). Serum amyloid P component has been re-
portedtointerferewithproperdin’sabilitytobindtocomplement
activatorsurfaces(30).AlthoughzymosanandGMPcontainboth
1¡3 and 1¡6 glucan linkages and activated the AP in the
presence of properdin, C3 was minimally activated by these par-
ticles in the absence of properdin. We speculate that mannans
present on the surfaces of zymosan and GMP may limit covalent
linkageformationbetweennascentC3bandtheunderlying1¡3
glucans. The ﬁnding that properdin is required for AP activation
by mannan-coated particles may be clinically relevant, consider-
ing the fact that most pathogenic fungi have an outer mannan
layer.
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antigenloading(20,21,35),theycanserveasaneffectiveantigen-
presenting cell receptor-targeted vaccine delivery system. Re-
cently, orally administered -glucan particles have also been
shown to function as effective adjuvants for tumor immunother-
apy (45). Although the relative contributions of complement re-
ceptors and -glucan receptors remain to be deﬁned, efﬁcient
coating of 1¡3 linkage-containing particles such as GP with C3
fragments likely contributes to their excellent ability to act as an
adjuvant. Goodridge et al. (46) recently demonstrated that
Dectin-1, a pattern recognition receptor, was activated only by
particulate -glucans and not by soluble -glucans (46). Particu-
late -glucans clustered around the receptor to form synapse-like
structures activating phagocytosis (46). Binding of C3 fragments
to antigens facilitates their uptake by subcapsular sinus macro-
phages in lymph nodes (47). Transfer of the antigen-C3 fragment
complexes to mature B cells involves binding of the C3d-coated
antigen to the B cell coreceptor (CD21/CD19/CD81), which low-
ers the threshold for B cell activation (48) and results in B cell
expansion and migration to the T cell-B cell boundary in lymph
nodes. Following interaction with follicular T helper cells, B cells
undergo somatic cell hypermutation and class switch recombina-
tionanddevelopintoplasmacellsormemoryBcells(reviewedin
reference 47). Our observations regarding how properdin facili-
tates AP activation by glucans in fungal cell walls contributes to
ourunderstandingofthecomplexityofcomplementactivationby
fungi and has implications for the use of glucan particles in bio-
medical applications.
MATERIALS AND METHODS
Particles used in this study. Glucan particles (GP) and glucan-mannan
particles(GMP)werepreparedfromSaccharomycescerevisiaeusingasuc-
cessionofalkalineandacidicextractionstepsaspreviouslydescribed(21,
31, 35, 36). GP are comprised of 85% 1¡6 branched 1¡3 D-glucan
polymers, 2% chitin, and 1% lipids and protein, with the remainder
being mostly ash and moisture, and GMP are comprised of ~50% 1¡6
branched 1¡3 D-glucan polymers, ~20% mannans, ~15% protein, 1%
chitin, and 1% lipids (31, 49). Zymosan (-glucans, mannans, and chi-
tin),alsopreparedfromS.cerevisiae,wasobtainedfromSigma(St.Louis,
MO). All particulate and soluble glycans used in this study and their
source and linkage composition are listed in Table 1.
Sera and complement reagents. Hemolytically active sera obtained
from 10 healthy adults (normal human serum [NHS]) were pooled and
storedat–80°Cuntilused.Topermitselectiveactivationofthealternative
pathway (AP), NHS was treated with 10 mM EGTA and 10 mM Mg2
(Mg-EGTA-NHS). The role of properdin in AP was determined by using
Mg-EGTA-treatedproperdin-depletedserum(P-depletedserum;catalog
no. A512; Quidel), or Mg-EGTA-NHS containing antiproperdin mono-
clonal antibody (MAb) (catalog no. A233 [see below]; Quidel) used at a
ﬁnal concentration of 50 g/ml as described previously (27). Serum de-
pleted of C3 by immunoafﬁnity chromatography was purchased from
Complement Technology, Inc., Tyler, TX (catalog no. A314). C3 was pu-
riﬁedfromhumanplasmabypolyethyleneglycol(PEG)precipitationand
DEAE Sephacel chromatography as described previously (50). The ﬁnal
concentration of serum in all reaction mixtures was 40%. In some exper-
iments, all complement pathways were inactivated by heating serum for
30 min at 56°C.
Antibodies. Two antiproperdin MAbs were purchased from Quidel
(catalogno.A233andA235).MAbA233blocksproperdinfunction,while
MAbA235bindstoproperdinbutdoesnotblockthefunctionofproper-
din. C3 (C3b plus iC3b) deposition on GP and zymosan was detected by
anti-human C3c conjugated to ﬂuorescein isothiocyanate (FITC) from
BioDesign (now Meridian Life Science, Inc., Saco, ME) for both ﬂow
cytometry and confocal microscopy. For Western blot analysis, C3 depo-
sitionwasdetectedusingafﬁnity-puriﬁedsheepanti-humanC3antibody
(Immunology Consultants Laboratory, Newburg, OR) followed by anti-
sheep IgG alkaline phosphatase (Sigma).
C3 deposition and properdin binding to GP and zymosan by ﬂow
cytometry. C3 deposition on GP and zymosan was determined by ﬂow
cytometry. Brieﬂy, 10 g of GP or zymosan particles were suspended in
Hanks’balancedsaltsolution(HBSS).BecauseGPandzymosanparticles
aresimilarlysizedandshaped,anapproximatelyequalamountofsurface
area should have been available for both types for C3 deposition. The
particles were washed once with HBSS containing 10 mM EGTA and
10 mM Mg2 (HBSS-Mg-EGTA) and incubated for 30 min at 37°C with
either NHS (all complement pathways active), Mg-EGTA-NHS (only AP
active), or heat-inactivated NHS (complement activity inactivated). A
reaction mixture that lacked serum was also included as a control. Total
C3 (C3b plus iC3b) deposited on GP or zymosan was detected by ﬂow
cytometry using FITC-conjugated anti-C3c antibody as described previ-
ously(51,52).TodemonstratethedependenceofC3depositiononGPor
zymosan for properdin binding, particles were incubated with C3-
depleted serum (Complement Technologies, Inc.) or C3-depleted serum
reconstituted with C3 to a concentration of 1 mg/ml, and binding of
properdin was determined using anti-human properdin MAb (catalog
no. A235; Quidel) at a dilution of 1:100, followed by anti-mouse IgG
conjugated to Alexa Fluor 647 (1:400) as described previously (27). Posi-
tive and negative controls included particles incubated with Mg-EGTA-
NHS or Mg-EGTA-treated, properdin-depleted serum (Quidel), respec-
tively.DatawerecollectedonanLSRIIﬂowcytometer(BectonDickinson
[Franklin Lakes, NJ]) and analyzed using the FlowJo analysis software
program (version 7.2.4; TreeStar Inc. [Ashland, OR]).
Confocal microscopy. C3 fragment deposition on and properdin
binding to GP and zymosan were also examined by confocal microscopy.
Brieﬂy, 10 g of GP or zymosan was washed once with HBSS-Mg-EGTA
and incubated with either Mg-EGTA-NHS or Mg-EGTA-treated,
properdin-depleted serum for time points between 10 and 30 min. The
particles were washed three times, and C3 and properdin associated with
GP or zymosan were detected using FITC-conjugated anti-C3c and anti-
human properdin MAb (catalog no. A235; Quidel) at a dilution of 1:100,
followed by anti-mouse IgG conjugated to Alexa Fluor 647 (1:400). The
stained particles were resuspended in HBSS containing 1% paraformal-
dehyde and spotted onto a 35-mm petri dish with a 10-mm microwell
(MatTek Corporation, Ashland, MA) and imaged using a 63 plan apo-
chromatobjectivelens(Zeiss)withaninvertedTCSSP2AOBSlaserscan-
ningconfocalmicroscope(Leica,Wetzlar,Germany).Todemonstratethe
dependenceofC3depositiononGPorzymosanforproperdinbindingby
confocal microscopy, the particles were incubated with C3-depleted se-
rum that had been treated with Mg-EGTA (C3-depleted serum-Mg-
EGTA) or C3-depleted serum-Mg-EGTA reconstituted with puriﬁed C3
(1 mg/ml) at 37°C for 30 min. Positive and negative controls included
incubation of particles with Mg-EGTA-NHS and Mg-EGTA-treated,
properdin-depleted serum, respectively. The particles were washed three
times, and properdin associated with GP or zymosan was detected using
anti-human properdin MAb (catalog no. A235; Quidel) at a dilution of
1:100,followedbyanti-mouseIgGconjugatedtoAlexaFluor647(1:400).
The stained particles were resuspended in HBSS containing 1% parafor-
maldehyde and imaged as mentioned above.
C3a and C5a assays. Activation of C3 is accompanied by release into
solution of the C3a fragment from the N terminus of the  chain of C3.
Furthermore, AP activation results in formation of C5 convertase
(C3bC3b,Bb)thatcleavesC5andreleasestheC5afragment.Brieﬂy,10g
of each glycan particle or soluble glycan (listed in Table 1) was incubated
at 37°C for 30 min with 40% NHS–Mg-EGTA alone or with 40% NHS–
Mg-EGTA containing MAb 233, which blocks properdin function, or
40% NHS–Mg-EGTA depleted of properdin. Reactions were stopped by
adding EDTA to a ﬁnal concentration of 20 mM, and particles were sep-
arated from the supernatants by centrifugation at 10,000  g for 5 min.
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using the MicroVue C3a enzyme immunoassay (EIA) kit (catalog no.
A015; Quidel) or the MicroVue C5a EIA kit (catalog no. A021; Quidel),
respectively.
AP-mediated C3 deposition on glycan particles. C3 fragment depo-
sitiononglycanparticleswasdeterminedbyWesternblottingasdescribed
previously(53).Brieﬂy,10gofeachoftheparticleslistedinTable1was
incubatedwitheitherMg-EGTA-NHS-orMg-EGTA-treatedserumcon-
taining antiproperdin MAb 233 (ﬁnal serum concentration of 40% [vol/
vol])inaﬁnalreactionvolumeof100lfor30minat37°C.Theparticles
were washed four times in HBSS and lysed in 4 lithium dodecyl sulfate
(LDS) sample buffer (Invitrogen) containing 10% 2-mercaptoethanol
(2-ME). The proteins were separated on NuPAGE Novex 4 to 12% Bis-
Tris gradient gels using NuPAGE 3-morpholinopropanesulfonic acid
running buffer (Invitrogen). The proteins were transferred to a polyvi-
nylidene diﬂuoride (PVDF) membrane (Millipore, Billerica, MA), and
C3 fragments were detected using afﬁnity-puriﬁed sheep anti-human
C3antibodyfollowedbygoatanti-sheepIgGconjugatedtoalkalinephos-
phatase.
Statisticalanalysis.DifferencesbetweenC3aandC5agenerationwere
calculated between the C3a and C5a generated by NHS-Mg-EGTA in the
presence or absence of functional properdin alone compared to glycans
incubated with the corresponding serum using one-way analysis of vari-
ance (ANOVA) followed by the Tukey-Kramer test (GraphPad InStat,
San Diego, CA).
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